Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,797 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type 1 Diabetes Clear all
Completed Phase 3 Interventional Results available

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

NCT03977727
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Fiasp®, Novolog®, 670G hybrid closed loop continuous subcutaneous insulin infusion system
Drug · Device
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Not applicable Interventional

Group Education Curriculum for Older Teens With Type 1 Diabetes

NCT03147274
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Intervention
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122
View directory record Official record
Conditions
Type 1 Diabetes, Dawn Phenomenon
Interventions
Lantus (glargine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 15, 2026, 6:57 AM EDT
Completed No phase listed Observational Results available

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

NCT00229658
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 15, 2026, 6:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implantable Antenna Sensors for Continuous Glucose Monitoring

NCT00596323
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Study Medication (MBX-2982), No medication for this group
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 15, 2026, 6:57 AM EDT
Terminated Phase 2 Interventional Results available

Inducing Remission in Type 1 Diabetes With Alefacept

NCT00965458
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Alefacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 15, 2026, 6:57 AM EDT
Withdrawn Phase 2 Interventional

A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II

NCT01183455
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Aralast NP, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 15, 2026, 6:57 AM EDT
Recruiting Not applicable Interventional

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

NCT07560813
View directory record Official record
Conditions
Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions
Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
Dietary Supplement · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Not applicable Interventional

Study of Arginine and Nitric Oxide in Patients With Diabetes

NCT03566524
View directory record Official record
Conditions
Ketosis Prone Diabetes
Interventions
Citrulline, Alanine
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 15, 2026, 6:57 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Imaging of Type 1 Diabetes Progression

NCT01521520
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ferumoxytol
Drug
Lead sponsor
Jason Gaglia
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

NCT01621776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Apidra, Humalog, Novolog
Drug
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 14 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
DeLeon Springs, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

Extended Bolus for Meals in a Closed-loop System

NCT05454891
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 insulin pump: Extended bolus of insulin then standard bolus of insulin, Tandem t:slim X2 insulin pump: Standard bolus of insulin then extended bolus of insulin
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 6:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Molecular Quantification of Insulin mRNA

NCT00324207
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 17 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Oct 15, 2026, 6:57 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06562907
View directory record Official record
Conditions
Weight Management
Interventions
GS-4571, Placebo, Omeprazole
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes

NCT00014911
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

An Outpatient Pump Shutoff Pilot Feasibility and Safety Study

NCT01736930
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pump suspension
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 15, 2026, 6:57 AM EDT
Active, not recruiting Phase 2 Interventional

Reducing Innate Inflammation in New Onset Type 1 Diabetes

NCT04335656
View directory record Official record
Conditions
Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions
Lactiplantibacillus plantarum, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 15, 2026, 6:57 AM EDT
Active, not recruiting Not applicable Interventional

Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)

NCT04387422
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Experimental hyperglycemia
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

NCT00592072
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medium chain fatty acid (Octanoic and Decanoic acid), Splenda (Placebo Control)
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 15, 2026, 6:57 AM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 15, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Results available

Pancreatic Islet Cell Transplantation

NCT00214786
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Islet cell transplantation
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 15, 2026, 6:57 AM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 15, 2026, 6:57 AM EDT